Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLATRA: Olaparib Maintenance After Trabectedin+PLD in Recurrent Ovarian Cancer
NCT03470805Phase 2Completed
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
- Start
- Jun 2018
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in ovarian cancer, sponsored by Grupo Español de Investigación en Cáncer de Ovario. Started Jun 2018; status: completed.
02
Drugs
olaparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03470805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03470805.